Physician profile
Robert Benton
NPI 1205820727
$1,676.61
in general payments reported to CMS, 2019-2025
18 companies · $269 in 2025
The $269 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.38 · 2020: $24.03 · 2021: $157 · 2022: $101 · 2023: $482 · 2024: $569 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,320.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $916.90 | 2019-2025 | |
| Abbott Laboratories | $270.61 | 2020-2025 | Mitraclip |
| Pfizer INC. | $73.92 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $70.29 | 2024 | Arcalyst |
| Boston Scientific Corporation | $57.06 | 2025 | Farapulse |
| Ge Healthcare | $51.69 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $50.90 | 2022-2024 | Camzyos |
| Cvrx, INC. | $43.65 | 2022 | |
| Novo Nordisk INC | $21.12 | 2023 | Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.59 | 2024 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $19.36 | 2023 | Uptravi |
| Amgen INC. | $17.47 | 2023 | Repatha |
| Merck Sharp & Dohme LLC | $16.96 | 2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $16.86 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.50 | 2023 | Jardiance |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $14.73 | 2024 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Benton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.